Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SOPHiA GENETICS ( (SOPH) ) has issued an announcement.
SOPHiA GENETICS announced its annual general meeting scheduled for June 18, 2025. In 2024, the company achieved significant milestones, including the acquisition of 92 new genomics customers and the expansion of its SOPHIA DDM™ Platform, resulting in a 23% growth in clinical revenue in the US. The company also launched new applications, MSK-ACCESS® and MSK-IMPACT®, and formed strategic partnerships to enhance its offerings and market reach.
Spark’s Take on SOPH Stock
According to Spark, TipRanks’ AI Analyst, SOPH is a Neutral.
SOPHiA GENETICS shows potential through strong revenue growth and new customer acquisitions, particularly in the U.S. and with new applications. However, significant challenges remain, including profitability issues, flat revenue growth, and increased leverage. Technical indicators suggest cautious sentiment, and with a negative P/E ratio, valuation remains a concern. Although there is optimism for future growth, current financial instability and market volatility contribute to a moderate overall score.
To see Spark’s full report on SOPH stock, click here.
More about SOPHiA GENETICS
SOPHiA GENETICS is a company operating in the healthcare industry, specializing in data-driven analytics and artificial intelligence to enhance patient care. Their primary product, the SOPHIA DDM™ Platform, is widely used for analyzing and interpreting human disease, with a focus on providing equal access to high-quality care globally.
Average Trading Volume: 54,899
Technical Sentiment Signal: Sell
Current Market Cap: $200.5M
See more insights into SOPH stock on TipRanks’ Stock Analysis page.